A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI)

Therapeutics and Clinical Risk Management

Volumn 4, Issue 1, 2008, Pages 235-244

  Dunbar, Lala M ^a   Tang, Derek M ^b   Manausa, Robert M ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

MRSA; Telavancin; Vancomycin

Indexed keywords

DAPTOMYCIN; LINEZOLID; PENICILLIN G; TELAVANCIN; VANCOMYCIN;

ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; CLINICAL TRIAL; CONSTIPATION; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; ENDOCARDITIS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; EUROPE; GOLD STANDARD; GRAM POSITIVE BACTERIUM; HUMAN; INSOMNIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NONHUMAN; PENICILLIN RESISTANT STREPTOCOCCUS PNEUMONIAE; PNEUMONIA; QT PROLONGATION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; SURGICAL INFECTION; TASTE DISORDER; TREATMENT INDICATION; UNITED STATES; URINE; VANCOMYCIN RESISTANT ENTEROCOCCUS; VANCOMYCIN RESISTANT ENTEROCOCCUS FAECALIS; VANCOMYCIN RESISTANT ENTEROCOCCUS FAECIUM; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS; VOMITING;

EID: 41549139187     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Barriere SF, Genter F, et al. 2004. Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J Clin Pharmacol, 44:689-95.
2. Beauregard DA, Williams DH, et al. 1995. Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics. Antimicrob Agents Chemother, 39:781-5.
3. CDC. 2002a. Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR Morb Mortal Wkly Rep, 51:565-7.
4. CDC. 2002b. Vancomycin-resistant Staphylococcus aureus - Pennsylvania, 2002. MMWR Morb Mortal Wkly Rep, 51:902.
5. Chambers HF. 2001. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis, 7:78-82.
6. [CLSI] Clinical and Laboratory Standards Institute. 2007. Performance Standards for Antimicrobial Susceptibility Testing; Seventeenth Informational Supplement M100-S17. Volume, DOI:
7. Corey R, Stryjewski M, et al. 2006. Telavancin for the treatment of complicated skin and skin structure infections (cSSSI): results of the ATLAS I study. 44th Infectious Disease Society of America. Toronto, Canada.
8. Davis SL, Perri MB, et al. 2007. Epidemiology and outcomes of community-associated methicillin-resistant Staphylococcus aureus infection. J Clin Microbiol, 45:1705-11.
9. Draghi D, Jones M, Thornsberry C, et al. 2005. Telavancin activity against current and diverse Staphylococcus aureus populations. 45th Interscience Conference on Antimicrobial Agents and Cemotherapy. Washington D.C., USA.
10. Draghi DC, Benton BM, et al. 2006. Baseline antistaphylococcal profile of telavancin: Results of the 2004-2005 US Surveillance Initiative. 46th Annual ICAAC. San Francisco, CA.
11. Drew RH. 2007. Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections. Pharmacotherapy, 27:227-49.
12. Duchin K, Shaw J, et al. 2004. Single dose pharmacokinetics (PK) of telavancin (TLV) in healthy elderly subjects. 14th European Congress of Clinical Microbiology and Infectious Diseases. Prague, Czech Republic.
13. Finegold SM, Song Y, et al. 2005. Clostridium clostridioforme: a mixture of three clinically important species. Eur J Clin Microbiol Infect Dis, 24:319-24.
14. Goldstein EJ, Citron DM, et al. 2004. In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp. Antimicrob Agents Chemother, 48:2149-52.
15. Goossens H. 2006. Antibiotic resistance: Highlights of the 16th European Congress on Clinical Microbiology and Infectious Diseases. 16th European Congress on Clinical Microbiology and Infectious Diseases, Nice, France.
16. Hegde SS, Reyes N, et al. 2004. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. Antimicrob Agents Chemother, 48:3043-50.
17. Hershow RC, Khayr WF, et al. 1998. Ciprofloxacin resistance in methicillin-resistant Staphylococcus aureus: associated factors and resistance to other antibiotics. Am J Ther, 5:213-20.
18. Higgins DL, Chang R, et al. 2005. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother, 49:1127-34.
19. Hiramatsu K, Hanaki H, et al. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother, 40:135-6.
20. Hooper DC. 1999. Mechanisms of fluoroquinolone resistance. Drug Resist Updat, 2:38-55.
21. Jansen WT, Verel A, et al. 2007. In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe. Antimicrob Agents Chemother, 51:3420-4.
22. Jevons M. 1961. Celbenin-resistant staphylococci. BMJ, 1:124-5.
23. Johnson AP, Aucken HM, et al. 2001. Dominance of EMRSA-15 and -16 among MRSA causing nosocomial bacteraemia in the UK: analysis of isolates from the European Antimicrobial Resistance Surveillance System (EARSS) J Antimicrob Chemother, 48:143-4.
24. Judice JK, Pace JL. 2003. Semi-synthetic glycopeptide antibacterials. Bioorg MedChem Lett, 13:4165-9.
25. Laohavaleeson S, Kuti JL, et al. 2007. Telavancin: a novel lipoglycopeptide for serious gram-positive infections. Expert Opin Investig Drugs, 16:347-57.
26. Leadbetter MR, Adams SM, et al. 2004. Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424). J Antibiot (Tokyo), 57:326-36.
27. Leuthner KD, Cheung CM, et al. 2006. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother, 58:338-43.
28. Levine DP. 2006. Vancomycin: a history. Clin Infect Dis, 42(Suppl 1): S5-12.
29. Madrigal AG, Basuino L, et al. 2005. Efficacy of telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother, 49 3163-5.
30. Maor Y, Rahav G, et al. 2007. Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center. J Clin Microbiol, 45:1511-4.
31. Moellering RC Jr. 2006. Vancomycin: a 50-year reassessment. Clin Infect Dis, 42(Suppl 1):S3-4.
32. Moran GJ, Krishnadasan A, et al. 2006. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med, 355:666-74.
33. Nishimura S, Tsurumoto T, et al. 2006. Antimicrobial susceptibility of Staphylococcus aureus and Staphylococcus epidermidis biofilms isolated from infected total hip arthroplasty cases. J Orthop Sci, 11:46-50.
34. Odenholt I, Lowdin E, et al. 2007. Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model. Antimicrob Agents Chemother, 51:3311-6.
35. Patel J, Grio M, et al. 2006a. Telavancin pharmacokinetics during in vitro continuous venovenous hemodialysis. 16th European Congress of Clinical Microbiology and Infectious Diseases. Nice, France. 1539.
36. Patel J, Grio M, et al. 2006b. Telavancin transmembrane clearance during in vitro continuous venovenous hemofiltration. 16th European Congress of Clinical Microbiology and Infectious Diseases. Nice, France. 1538.
37. Pfizer. 2007. "http://www.pfizer.com." Accessed 23 June 2007 URL: http://www.pfizer.com.
38. Reyes N, Skinner R, et al. 2006. Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother, 58:462-5.
39. Reyes N, Skinner R, et al. 2005. Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother, 49:4344-6.
40. Rice LB. 2006. Antimicrobial resistance in gram-positive bacteria. Am J Med, 119(Suppl 1):S11-9; discussion S62-70.
41. Sakoulas G, Moellering RC Jr, et al. 2006. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. Clin Infect Dis, 42(Suppl 1):S40-50.
42. Saravolatz LD, Pawlak J, et al. 2007. Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother, 60:406-9.
43. Shaw JP, Seroogy J, et al. 2005. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother, 49:195-201.
44. Spink W, Ferris V. 1945. Quantitative action of penicillin inhibitor from penicillin-resistant strains in staphylococci. Science, 102:221-3.
45. Stevens DL, 2006. The role of vancomycin in the treatment paradigm. Clin Infect Dis, 42(Suppl 1):S51-7.
46. Stryjewski ME, Chu VH, et al. 2006. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother, 50:862-7.
47. Stryjewski ME, O'Riordan WD, et al. 2005. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis, 40:1601-7.
48. Styers D, Sheehan DJ, et al. 2006. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann Clin Microbiol Antimicrob, 5:2.
49. Sun HK, Duchin K, et al. 2006. Tissue penetration of telavancin after intravenous administration in healthy subjects. Antimicrob Agents Chemother, 50:788-90.
50. Swartz MN. 1994. Hospital-acquired infections: diseases with increasingly limited therapies. Proc Natl Acad Sci USA, 91:2420-7.
51. Talbot GH, Bradley J, et al. 2006. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis, 42:657-68.
52. Van Bambeke F. 2004. Glycopeptides in clinical development: pharmacological profile and clinical perspectives. Curr Opin Pharmacol, 4:471-8.
53. Wong S, Shaw J, et al. 2007. Penetration of telavancin into pulmonary epithelial lining fluid and alveolar macrophages. 17th European Congress of Clinical Microbiology and Infectious Diseases. ICC, Munich, Germany.
54. Wong S, Shaw JP, et al. 2006. Pharmacokinetics of intravenous telavancin in subjects with hepatic impairment. 2006 ICAAC Meeting. San Francisco, CA.